Insmed | INSM - Cash And Equivalent


Insmed reported $334.76M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
DBV Technologies USD 69.84M 33.37M Sep/2025
Dynavax Technologies USD 160.25M 61.15M Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Insmed USD 334.76M 949.56M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025